Comparison cloud indicating the words that appeared most frequently with regard to each type of lecturer (lecturers from the USA, top, blue colour; lecturers not from the USA, bott... by Ignacio García-Espona (21395335)

Subjects:

Global number of lectures and posters (2013-2023). by Ignacio García-Espona (21395335)

Subjects:

Comparison cloud for posters indicating the words that appeared most frequently in each period (2013-2017, top, blue colour; 2018-2023, bottom, red colour). by Ignacio García-Espona (21395335)

Subjects:

Poster ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Kore... by Ignacio García-Espona (21395335)

Subjects:

Lectures by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan, US... by Ignacio García-Espona (21395335)

Subjects:

Lectures by country and year [Top 2-10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan). by Ignacio García-Espona (21395335)

Subjects:

Lecturer ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Ko... by Ignacio García-Espona (21395335)

Subjects:

Sample Data. by Ignacio García-Espona (21395335)

Subjects:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects:

The effect of MAGMAS inhibition on mitochondrial respiration and acidification rate in D425 cells. by Zahra Motahari (6814013)

Subjects:

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition on mitochondrial activity in medulloblastoma cells. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition reduces DAOY cells migration. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

Subjects:

BT9 reduces DAOY and D425 medulloblastoma cell invasion. by Zahra Motahari (6814013)

Subjects:

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)

Subjects:

BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

Subjects:

TMS recapitulates epigenetic age predictions and tissue-dependent effects identified via other technologies. by Amy Longtin (21409957)